Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.

التفاصيل البيبلوغرافية
العنوان:	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
المؤلفون:	Jackson LR 2nd; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC larry.jackson@dm.duke.edu., Peterson ED; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., McCoy LA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Ju C; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Zettler M; Eli Lilly & Company, Indianapolis, IN., Baker BA; Daiichi Sankyo, Inc, Parsippany, NJ., Messenger JC; University of Colorado School of Medicine, Aurora, CO., Faries DE; Eli Lilly & Company, Indianapolis, IN., Effron MB; Eli Lilly & Company, Indianapolis, IN., Cohen DJ; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO., Wang TY; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
المصدر:	Journal of the American Heart Association [J Am Heart Assoc] 2016 Oct 21; Vol. 5 (10). Date of Electronic Publication: 2016 Oct 21.
نوع المنشور:	Comparative Study; Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Oxford : Wiley-Blackwell
مواضيع طبية MeSH:	Acute Coronary Syndrome/drug therapy , Myocardial Infarction/drug therapy , Prasugrel Hydrochloride/therapeutic use , Proton Pump Inhibitors/therapeutic use , Purinergic P2Y Receptor Antagonists/therapeutic use , Ticlopidine/analogs & derivatives, Acute Coronary Syndrome/surgery ; Aftercare ; Aged ; Cardiovascular Diseases/mortality ; Clopidogrel ; Comparative Effectiveness Research ; Female ; Gastrointestinal Hemorrhage/chemically induced ; Gastrointestinal Hemorrhage/epidemiology ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Myocardial Infarction/surgery ; Myocardial Revascularization/statistics & numerical data ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors/therapeutic use ; Proportional Hazards Models ; Recurrence ; Stroke/epidemiology ; Ticlopidine/therapeutic use ; Treatment Outcome
مستخلص:	Background: Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism. We sought to understand the comparative effectiveness and safety of prasugrel versus clopidogrel in the context of proton pump inhibitor (PPI) use. Methods and Results: Using data on 11 955 acute myocardial infarction (MI) patients treated with percutaneous coronary intervention at 233 hospitals and enrolled in the TRANSLATE-ACS study, we compared whether discharge PPI use altered the association of 1-year adjusted risks of major adverse cardiovascular events (MACE; death, MI, stroke, or unplanned revascularization) and Global Use of Strategies To Open Occluded Arteries (GUSTO) moderate/severe bleeding between prasugrel- and clopidogrel-treated patients. Overall, 17% of prasugrel-treated and 19% of clopidogrel-treated patients received a PPI at hospital discharge. At 1 year, patients discharged on a PPI versus no PPI had higher risks of MACE (adjusted hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.21-1.58) and GUSTO moderate/severe bleeding (adjusted HR 1.55, 95% CI 1.15-2.09). Risk of MACE was similar between prasugrel and clopidogrel regardless of PPI use (adjusted HR 0.88, 95% CI 0.62-1.26 with PPI, adjusted HR 1.07, 95% CI 0.90-1.28 without PPI, interaction P=0.31). Comparative bleeding risk associated with prasugrel versus clopidogrel use differed based on PPI use but did not reach statistical significance (adjusted HR 0.73, 95% CI 0.36-1.48 with PPI, adjusted HR 1.34, 95% CI 0.79-2.27 without PPI, interaction P=0.17). Conclusions: PPIs did not significantly affect the MACE and bleeding risk associated with prasugrel use, relative to clopidogrel. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01088503. (© 2016 The Authors and Eli Lilly & Company. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
References:	Clin Pharmacokinet. 1996 Jul;31(1):9-28. (PMID: 8827397) Thromb Haemost. 2009 Apr;101(4):714-9. (PMID: 19350116) JAMA. 2009 Mar 4;301(9):937-44. (PMID: 19258584) J Thromb Haemost. 2006 Nov;4(11):2508-9. (PMID: 16898956) N Engl J Med. 2001 Aug 16;345(7):494-502. (PMID: 11519503) J Am Coll Cardiol. 2010 Dec 7;56(24):2051-66. (PMID: 21126648) Am Heart J. 2015 Oct;170(4):683-694.e3. (PMID: 26386792) J Am Coll Cardiol. 2001 Jun 15;37(8):2240-5. (PMID: 11419906) N Engl J Med. 2010 Nov 11;363(20):1909-17. (PMID: 20925534) Circulation. 2007 Dec 18;116(25):2923-32. (PMID: 18056526) Am Heart J. 2011 Nov;162(5):844-51. (PMID: 22093200) J Am Coll Cardiol. 2008 Jan 22;51(3):256-60. (PMID: 18206732) Am Heart J. 2015 Oct;170(4):706-14. (PMID: 26386794) Lancet. 2009 Sep 19;374(9694):989-97. (PMID: 19726078) N Engl J Med. 2007 Nov 15;357(20):2001-15. (PMID: 17982182) Drug Metab Dispos. 2004 Aug;32(8):821-7. (PMID: 15258107) N Engl J Med. 1993 Sep 2;329(10):673-82. (PMID: 8204123)
فهرسة مساهمة:	Keywords: bleeding risk; clopidogrel; major adverse cardiovascular events; prasugrel; proton pump inhibitors
سلسلة جزيئية:	ClinicalTrials.gov NCT01088503
المشرفين على المادة:	0 (Platelet Aggregation Inhibitors) 0 (Proton Pump Inhibitors) 0 (Purinergic P2Y Receptor Antagonists) A74586SNO7 (Clopidogrel) G89JQ59I13 (Prasugrel Hydrochloride) OM90ZUW7M1 (Ticlopidine)
تواريخ الأحداث:	Date Created: 20161030 Date Completed: 20171219 Latest Revision: 20181202
رمز التحديث:	20221213
مُعرف محوري في PubMed:	PMC5121485
DOI:	10.1161/JAHA.116.003824
PMID:	27792656
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	2047-9980
DOI:	10.1161/JAHA.116.003824